HuLA immune Overview

  • Founded
  • 2017
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $884K
Latest Deal Amount
  • Investors
  • 2

HuLA immune General Information

Description

Operator of a drug development company intended to target and cure diseases. The company leverages technology to develop innovative drugs to cure autoimmune diseases and cancer based on microbiology and immunology research, provided medical professionals with cure for rare diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • SENQ Kasumigaseki,1-4-1 Kasumigaseki
  • Chiyoda-ku
  • Tokyo, 100-0013
  • Japan
+81 00-0000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HuLA immune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 12-Dec-2018 $884K 00000 Completed Startup
To view HuLA immune’s complete valuation and funding history, request access »

HuLA immune Executive Team (1)

Name Title Board Seat Contact Info
Yasuhiro Shindo Ph.D Chief Executive Officer & President & Board Member & Representative Director
To view HuLA immune’s complete executive team members history, request access »

HuLA immune Board Members (4)

Name Representing Role Since
Akihiro Tomoyasu Ph.D Self Board Member 000 0000
Fumio Nishikaku Ph.D HuLA immune Board Member & Advisor 000 0000
Shigeru Yasue HuLA immune Board Member & Advisor 000 0000
Yoshiyuki Osugi Ph.D HuLA immune Board Member & Advisor 000 0000
To view HuLA immune’s complete board members history, request access »

HuLA immune Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mitsubishi UFJ Capital Venture Capital Minority 000 0000 000000 0
Osaka University Venture Capital Venture Capital Minority 000 0000 000000 0
To view HuLA immune’s complete investors history, request access »